ASX AnnouncementsNew data shows PAT-DX3 able to cross the blood brain barrier12 Jul 20210In an exciting development, Patrys today announced new data confirming its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross…
News UpdateBioshares | June 20211 Jul 20210Patrys has been featured in the latest edition (Edition 896) of investor newsletter Bioshares. The article highlights our Company’s strong…
MediaStockhead V-Con Biotechs30 Jun 20210Patrys is delighted to be participating in the V-Con Biotechs conference this week. Presented by Stockhead, V-Con is an opportunity…
Media180 Markets Interview28 Jun 20210Patrys CEO and MD, Dr James Campbell, was recently interviewed by 180 Markets CEO and Co-Founder, Greg Lowe, to summarise…
MediaPatrys in The Australian16 Jun 20210Patrys appears on page 7 of The Australian today as part of a story secured with the newspaper’s Health Editor,…
ASX AnnouncementsNew Data | PAT-DX115 Jun 20210Patrys is pleased to announce the publication of new data in the highly-regarded Journal of Clinical Investigation – Insight, demonstrating…
NewsletterNewsletter | June 20216 Jun 20210Patrys is pleased to share its latest Newsletter, published June 2021. Key highlights: Letter from our CEO Media and analyst…
MediaFierce Biotech | Prof Peter Glazer13 May 20210Fierce Biotech has reported on another of Professor Peter Glazer’s start-up ventures. Peter also has experience working with our PAT-DX1…
News UpdateBioshares | February 202123 Feb 20210Patrys was featured in the latest issue of BioShares in an article titled, “Patrys Achieves Major Development Milestone”. Read it…
News UpdateBioshares | December 202018 Dec 20200Patrys was featured in the latest issue of BioShares in an article titled, “Patrys’ PAT-DX1 Hijacks a Nucleoside Transporter to…